Engineering the Next Generation of Small-Molecule Medicines
CRAFT Therapeutics
An AI-enabled precision prodrug company using the ALX Engine to transform established small-molecule drugs into differentiated assets designed to overcome clinical limitations.
Why ALX Matters
ALX creates structurally distinct small-molecule successor drugs before LOE closes. Pharma teams use ALX to protect franchises, differentiate pipeline assets, and unlock new commercial life for existing small molecules.
ALX compounds are new chemical entities (NCEs) — not reformulations.
CRAFT = Chemically Re-Architected Functional Therapeutics
One Platform, Multiple Value Layers
%20%20.png)
Better Products
Engineered therapeutics with improved safety, pharmacokinetics, and tissue distribution relative to the originator compound.
%20%20.png)
New Composition-of-Matter IP
Each ALX construct is a structurally distinct, new chemical entity, generating independent intellectual property protection.
%20%20.png)
Extended Commercial Life
New IP coverage and differentiated clinical profiles extend the commercial runway beyond loss-of-exclusivity timelines of the originator.
Existing Drugs Have Fixable Limitations
Approved small-molecule drugs carry well-documented limitations that create a clear opportunity for engineering-led improvement.
Safety Liabilities
On-target and off-target toxicity
PK Limitations
Suboptimal ADME profiles
Tissue Distribution Challenges
Poor selectivity for target tissue
Dosing Burden
Frequent dosing requirements
Loss of Exclusivity
Patent cliffs eroding commercial value
ALX Solution: A Modular Product-Profile Engineering Architecture
ALX is a modular architecture that combines three defined components to create structurally distinct, new therapeutic entities, not reformulations.
Activator
A clinically validated small-molecule drug as the active foundation.
Linker
Reversible linker enabling controlled release and modulated pharmacokinetics.
Effector
Tunable effector domain that modulates the overall therapeutic profile.
ALX Feasibility Criteria
- ✓Small-molecule drugs with clean conjugation handles
- ✓CRO-available bioassays
- ✓Biologically triggered linker compatibility (Val-Cit, amino acids, sugars, metabolites)
- ✓Small-molecule X-domains only (no peptides, proteins, polymers)
A Large, Repeatable Opportunity Universe
The addressable market for ALX is substantial, spanning both marketed drugs and pipeline candidates.
- ~70–80% of 3000+ marketed small molecules are structurally amenable
- Targets approved drugs with established safety and commercial profiles
- ~5,100–6,400 pipeline candidates applicable
- Spans early-stage through late-stage development
Multiple Paths to Value Creation
Pharma Partnerships
Licensing
Co-Development
Internal Development
About CRAFT Therapeutics
Building next-generation small-molecule medicines using the patent-pending ALX architecture.
For Pharma, CROs, and CDMOs
CRAFT partners with pharma IR teams, CROs, and manufacturing organizations to evaluate ALX feasibility, generate ALX variants, and license ALX molecules for development and manufacturing.
%20%20.png)
Partnership Inquiries
For pharma, CRO, CDMO, and manufacturing partners interested in ALX evaluation or licensing, we’d be happy to connect.